Xtl Biopharmaceuticals (XTLB) Non-Current Debt (2010 - 2017)

Xtl Biopharmaceuticals (XTLB) has reported Non-Current Debt for 3 consecutive years, with $2.7 million the latest figure, recorded in Q4 2017.

• Quarterly Non-Current Debt changed N/A year-over-year to $2.7 million in Q4 2017, while the trailing twelve-month figure through Dec 2017 was $2.7 million (changed N/A YoY) and the FY2017 annual result came in at $2.7 million, changed N/A from the prior year.
• Non-Current Debt slipped to $2.7 million in Q4 2017 per XTLB's latest filing, from $4.1 billion in the prior quarter.
• Over the last five years, Non-Current Debt for XTLB reached as high as $2.7 million in Q4 2017 and fell as low as $2.7 million in Q4 2017.